Mecanismos COMPLEMENTARIOS frecuentemente combinados por sinergia
Single and dual agonists The fundamental difference between these two molecules is that semaglutide is a GLP-1 agonist, i.e., it has a strong structural similarity (95%) with this hormone and specifically activates its receptor, while tirzepatide is a dual agonist, i.e., it has a hybrid structure that allows it to activate both GLP-1 and GIP receptors (Figure 2)
This pattern repeats with each dose increase, which is why slow titrationbeginning at low doses and increasing graduallyremains the clinical gold standard for maximizing tolerance
The peptide can be compounded with other nutrients like glycine or arginine for enhanced absorption
Gracias a esto, se ha convertido en una herramienta muy popular en el tratamiento del sobrepeso y la obesidad
In addition to the FDAs scrutiny of outsourcing facilities and compounders in the GLP-1 space, the FDA has expressed concerns over the use of unapproved GLP-1 drugs for weight loss, 2 including dosing concerns with compounded semaglutide and tirzepatide products, salt forms that should not be used to compound semaglutide, use of retatrutide in compounding, and adverse events related to compounded versions of semaglutide and tirzepatide, among others
